Ikarian Capital’s Altimmune ALT Stock Holding History

Ikarian Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000,000	Closed	-$3.77M	–	177
2025 Q3	$3.77M	Buy	1,000,000 +172,500	+21%	+$666K	0.38%	69
2025 Q2	$3.2M	Buy	+827,500	New	+$4.48M	0.62%	52
2025 Q1	–	Sell	-165,700	Closed	-$1.19M	–	165
2024 Q4	$1.19M	Buy	+165,700	New	+$1.27M	0.16%	100
2023 Q2	–	Sell	-898,600	Closed	-$3.79M	–	127
2023 Q1	$3.79M	Buy	898,600 +321,200	+56%	+$3.82M	0.86%	44
2022 Q4	$9.5M	Sell	577,400 -265,200	-31%	-$2.98M	2.29%	12
2022 Q3	$10.8M	Buy	842,600 +539,000	+178%	+$7.96M	2.14%	13
2022 Q2	$3.55M	Buy	+303,600	New	+$1.87M	0.65%	45

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ikarian Capital's ALT Position: Q2 2023 in Review

Ikarian Capital sold out of Altimmune (ALT) in Q2 2023, closing a stake of 677,300 shares — an estimated $2.86M sold.

Ikarian Capital first reported a position in ALT in Q2 2020 and held it in 8 quarters. The position peaked at $10.5M in Q2 2022. 120 funds tracked by Wall St. Rank hold ALT as of Q2 2023.

Ikarian Capital reported no remaining Altimmune position as of Q2 2023 after selling out during the quarter.
Ikarian Capital sold 677,300 Altimmune shares in Q2 2023, an estimated $2.86M.
Ikarian Capital first reported a position in Altimmune in Q2 2020 and held it in 8 quarters.
Ikarian Capital's Altimmune position peaked at $10.5M in Q2 2022.
120 funds tracked by Wall St. Rank held Altimmune as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.